{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Zoetis, Inc. overvalued or undervalued?
As of October 17, 2025, Zoetis, Inc. is fairly valued with a P/E ratio of 31, but has underperformed the S&P 500 with a year-to-date return of -11.58% compared to the index's 13.30%.
Zoetis, Inc. Experiences Valuation Adjustment Amidst Competitive Market Landscape
Zoetis, Inc. has recently adjusted its valuation, with a current P/E ratio of 31 and strong financial metrics, including a return on capital employed of 36.14% and a return on equity of 55.54%. The company remains competitive within the Pharmaceuticals & Biotechnology sector despite recent performance challenges.
Is Zoetis, Inc. overvalued or undervalued?
As of October 17, 2025, Zoetis, Inc. is fairly valued with a P/E ratio of 31, but has underperformed the S&P 500 with a year-to-date return of -11.58% compared to the index's 13.30%.
Is Zoetis, Inc. overvalued or undervalued?
As of October 17, 2025, Zoetis, Inc. is fairly valued with a P/E ratio of 31 and an EV to EBITDA of 21.76, but it has underperformed the S&P 500 with a YTD return of -11.58%, suggesting it may not be a compelling buy despite reasonable growth potential.
Zoetis Adjusts Valuation Grade, Signaling Strong Financial Performance and Investor Interest
Zoetis, Inc. has recently experienced a valuation grade adjustment, reflecting a more favorable assessment of its financial metrics and market position. The company demonstrates strong performance indicators, including a competitive P/E ratio, efficient management, and consistent sales growth, attracting significant institutional interest.
Zoetis, Inc. Experiences Revision in Its Stock Evaluation Amid Market Dynamics
Zoetis, Inc. has recently adjusted its valuation, with its current price at $146.42. Over the past year, the company has seen a 23.34% decline, contrasting with the S&P 500's gains. Key metrics include a P/E ratio of 31 and a strong return on equity of 55.54%.
Is Zoetis, Inc. overvalued or undervalued?
As of October 3, 2025, Zoetis, Inc. is considered an attractive investment due to its strong profitability indicated by a 55.54% ROE, despite a higher P/E ratio of 31 compared to the industry average of 27.30, and its stock has underperformed the S&P 500, suggesting it may be undervalued.
Zoetis Stock Hits Day High with Strong 3.68% Intraday Performance
Zoetis, Inc. has seen a significant rise in stock performance, reaching an intraday high and demonstrating strong market interest. The company maintains a high return on capital employed and a low debt to EBITDA ratio, while also reporting consistent profit growth and robust operating cash flow. Its market capitalization remains substantial.
Zoetis, Inc. Stock Plummets to New 52-Week Low of $139.34
Zoetis, Inc. has reached a new 52-week low, reflecting a notable decline in its stock price over the past year. With a market capitalization of USD 71,581 million, the company maintains a strong return on equity of 52.68% and a significant dividend yield, highlighting its commitment to shareholder value.
Is Zoetis, Inc. overvalued or undervalued?
As of August 28, 2025, Zoetis, Inc. is considered overvalued with a valuation grade of fair, reflected by high P/E, Price to Book, and EV to EBITDA ratios, and it has underperformed the S&P 500 with year-to-date and one-year returns of -9.72% and -25.13%, respectively.
Is Zoetis, Inc. technically bullish or bearish?
As of June 27, 2025, Zoetis, Inc. is in a bearish trend with moderate strength, indicated by daily moving averages and weekly Bollinger Bands, despite a mixed MACD signal.
Is Zoetis, Inc. overvalued or undervalued?
As of June 27, 2025, Zoetis, Inc. is fairly valued with a P/E ratio of 31 and strong profitability, but it underperformed the S&P 500 with a 1-year return of -11.50%, making it less attractively priced compared to some peers.
Is Zoetis, Inc. overvalued or undervalued?
As of May 1, 2025, Zoetis, Inc. is fairly valued with a P/E ratio of 31 and a recent stock performance lagging behind the S&P 500, indicating it may not be the most attractive investment compared to peers like Eli Lilly and Johnson & Johnson.
Is Zoetis, Inc. technically bullish or bearish?
As of May 15, 2025, Zoetis, Inc. shows a mildly bearish trend due to daily moving averages and weekly Bollinger Bands indicating bearish momentum, despite some mildly bullish signals from the MACD and KST, while overall monthly indicators remain bearish and the stock has underperformed against the S&P 500.
Who are in the management team of Zoetis, Inc.?
As of March 2022, the management team of Zoetis, Inc. includes Non-Executive Chairman Michael McCallister, CEO Kristin Peck, and Directors Antoinette Leatherberry, Paul Bisaro, Frank D'Amelio, and Sanjay Khosla. They oversee the company's strategic direction and operations.
What does Zoetis, Inc. do?
Zoetis, Inc. specializes in animal health medicines and vaccines, operating in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $2.22 billion and a market cap of approximately $76.59 billion.
How big is Zoetis, Inc.?
As of Jun 18, Zoetis, Inc. has a market capitalization of $76.59 billion, with net sales of $9.29 billion and net profit of $2.53 billion over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
